Chelerythrine is a potent, cell permeable inhibitor of protein kinase C (IC50 = 660 nM) that does not inhibit tyrosine protein kinases, cAMP-dependent protein kinase, or calcium/calmodulin-dependent protein kinase. Chelerythrine also inhibits Bcl-xL function (IC50 = 1.5 μM) by displacing Bax binding, inducing apoptosis in several cancer cell lines. Chelerythrine can also have PKC-independent effects, activate p38 MAP kinase and JUNK signaling pathways, and induce apoptosis in cancer cells both in vitro and in vivo.
Naturally occurring alkaloid. Cell-permeable, selective inhibitor of protein kinase C (IC50 = 660 nM). Acts on the catalytic domain irrespective of the attachment of the regulatory domain. Material is a competitive inhibitor with respect to the phosphate acceptor and a non-competitive inhibitor with respect to ATP. Over ten-fold more potent than H-7, HCl (Cat. No. 371955). Inhibits thromboxane formation and phosphoinositide metabolism in platelets. Also induces apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells.
1. j. m. herbert, j. m. augereau, j. gleye and j. p. maffrand, biochem biophys res commun 1990, 172, 993-999. 2. w. d. jarvis, a. j. turner, l. f. povirk, r. s. traylor and s. grant, cancer res 1994, 54, 1707-1714. 3. j. vrba, p. dolezel, j. vicar, m. modriansky and j. ulrichova, toxicol in vitro 2008, 22, 1008-1017. 4. m. vogler, k. weber, d. dinsdale, i. schmitz, k. schulze-osthoff, m. j. dyer and g. m. cohen, cell death differ 2009, 16, 1030-1039. 5. r. yu, s. mandlekar, t. h. tan and a. n. kong, j biol chem 2000, 275, 9612-9619. 6. s. yamamoto, k. seta, c. morisco, s. f. vatner and j. sadoshima, j mol cell cardiol 2001, 33, 1829-1848.
